[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,882
  • Shares Outstanding, K 58,235
  • Annual Sales, $ 66,800 K
  • Annual Income, $ 8,570 K
  • EBIT $ 14 M
  • EBITDA $ 14 M
  • 60-Month Beta 1.55
  • Price/Sales 1.05
  • Price/Cash Flow 8.02
  • Price/Book 1.60

Options Overview Details

View History
  • Implied Volatility 184.25% (+184.25%)
  • Historical Volatility 54.90%
  • IV Percentile 82%
  • IV Rank 25.70%
  • IV High 546.85% on 03/03/26
  • IV Low 58.84% on 05/04/26
  • Expected Move (DTE 20) 0.0000 (0.00%)
  • Put/Call Vol Ratio 5.37
  • Today's Volume 121
  • Volume Avg (30-Day) 88
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 8,635
  • Open Int (30-Day) 7,983
  • Expected Range 1.2000 to 1.2000

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) +262,994.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1250 +6.67%
on 08/03/26
1.3000 -7.69%
on 08/13/26
+0.0050 (+0.42%)
since 07/28/26
3-Month
1.0800 +11.11%
on 07/24/26
3.0673 -60.88%
on 06/04/26
-1.7000 (-58.62%)
since 05/28/26
52-Week
1.0800 +11.11%
on 07/24/26
3.0800 -61.04%
on 05/27/26
-0.8000 (-40.00%)
since 08/28/25

Most Recent Stories

More News
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and...

SPRO : 1.2000 (-0.83%)
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases  U.S. Food and Drug Administration approved...

SPRO : 1.2000 (-0.83%)
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology...

SPRO : 1.2000 (-0.83%)
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on...

SPRO : 1.2000 (-0.83%)
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology...

SPRO : 1.2000 (-0.83%)
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero’s clinical leadership team as the Company advances SP001, a Phase...

SPRO : 1.2000 (-0.83%)
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil)...

KKR : 108.68 (-0.59%)
SPRO : 1.2000 (-0.83%)
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate...

SPRO : 1.2000 (-0.83%)
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront...

SPRO : 1.2000 (-0.83%)
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize...

SPRO : 1.2000 (-0.83%)

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 1.2589
2nd Resistance Point 1.2395
1st Resistance Point 1.2197
Last Price 1.2000
1st Support Level 1.1805
2nd Support Level 1.1611
3rd Support Level 1.1413

See More

52-Week High 3.0800
Fibonacci 61.8% 2.3160
Fibonacci 50% 2.0800
Fibonacci 38.2% 1.8440
Last Price 1.2000
52-Week Low 1.0800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.